Globus Medical, Inc. (NYSE:GMED) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Globus Medical, Inc. (NYSE:GMED) have been assigned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are currently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $105.00.

Several brokerages have weighed in on GMED. BMO Capital Markets initiated coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They set an “outperform” rating and a $94.00 price objective on the stock. Stifel Nicolaus cut their target price on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research note on Wednesday, July 8th. Wells Fargo & Company reduced their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Piper Sandler decreased their price target on Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research report on Monday, June 15th. Finally, Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $78.54 on Thursday. Globus Medical has a 52 week low of $51.79 and a 52 week high of $101.40. The company’s fifty day moving average is $79.94 and its 200-day moving average is $86.59. The company has a market capitalization of $10.66 billion, a PE ratio of 18.26, a P/E/G ratio of 1.57 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter last year, the company posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, analysts forecast that Globus Medical will post 4.74 EPS for the current year.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 18.38% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Elevation Wealth Partners LLC lifted its position in Globus Medical by 2,178.6% during the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after buying an additional 305 shares in the last quarter. SBI Securities Co. Ltd. increased its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 167 shares in the last quarter. Advisory Services Network LLC acquired a new stake in Globus Medical in the 3rd quarter valued at about $26,000. EverSource Wealth Advisors LLC raised its stake in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of Globus Medical by 83.4% in the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock worth $46,000 after acquiring an additional 242 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.